* Plan for hotels near Anschutz Medical Campus moves forward
   
* University of Colorado Cancer Center names new director
   
* Five questions for John Jackson
   
* University's new expense system continues to roll
   
* President's Task Force on Efficiency seeks more suggestions
   
* Procurement Service Center launches redesigned Web site
   
* Sustainable practices program adds management certificate
   
* Conference to examine 'Islam and the Media'
   
* People
   
* Forum
 
 NEWS FROM THE CU SYSTEM
 
  CU-BOULDER
  Expert: State's economy to stabilize but still lose jobs in 2010
 
  UCCS
  Chancellor: University must grow to avoid financial 'cliff'
 
  UC DENVER
  Employee teams form to respond to community needs
 
  ANSCHUTZ MEDICAL CAMPUS
  Study highlights lack of knowledge regarding hospital medications
 
  TECH TRANSFER
  License agreement gives Viral Genetics Inc. right to develop cancer therapies
 
 
 
 
 
 
 
 
 
 
 
 
   Home
   Newsletter Archive
 
Download Newsleter in PDF
 
Share your thoughts
  FORUM
Share your opinion in a Letter to the Editor

CONTACT US
Send your thoughts and suggestions for the Newsletter

News from the CU system - Tech Transfer

License agreement gives Viral Genetics Inc. right to develop cancer therapies

Biotechnology company Viral Genetics (VRAL.PK) has entered into an exclusive license agreement with the University of Colorado to develop cancer therapies based on the work of M. Karen Newell, Ph.D., a professor of biology at the University of Colorado at Colorado Springs. This new line of research will be pursued by scientists at MetaCytoLytics Inc., a wholly owned subsidiary of Viral Genetics.

Newell has discovered a process called "metabolic disruption technology" (MDT), which blocks invasive cells' ability to generate energy from sugars or fatty acids. In essence, MDT "starves" cancer cells, causing them to die. As proof of principle, Newell's team at CU has performed more than 400 metabolic disruption technology experiments in vitro and in animal models.

"The team at Viral Genetics has the knowledge and experience to develop these technologies into products that may ultimately change the way we understand and develop drugs and processes for a variety of human related applications," said David Allen, CU associate vice president for technology transfer. The licensed intellectual property portfolio includes related technology developed by Newell at the University of Vermont.

"This agreement enables us to pursue new lines of research with Dr. Newell," said Viral Genetics CEO Haig Keledjian. "Her latest discoveries have tremendous potential to help patients with drug-resistant tumors, the leading cause of death due to cancer." According to Newell, MDT is expected to be combined with traditional chemotherapy and radiation treatments.

Newell believes that the same process may also be used to create more effective biofuels by increasing polyunsaturated fats in plant cells.

Bookmark - Print - Share

 
Previous Tech Transfer Stories

12/09/2009
Soligenix options CU vaccine technology

12/02/2009
Aurora company licenses CU technology for 3-D heart modeling

09/23/2009
Colorado firm aims to commercialize CU breakthroughs in pain management

09/16/2009
Office reports best year for invention disclosures

09/16/2009
Office invites bioscience faculty to submit grant proposals

09/02/2009
Reading software based on CU technology draws national attention

08/19/2009
CU startup to develop 'biogenerator' for medical devices

08/06/2009
CU startup licenses social networking iPhone app